Bifidobacterium Lactulose Optimization in Oncology and Microbiome (BLOOM)

University of Chicago

Summary

The purpose of this study is to see if lactulose can improve the effectiveness of immunotherapy in patients with advanced cancer.

Eligibility

Age range: 18+ years
Sex: All
Healthy volunteers: No

Detailed criteria

Inclusion Criteria: * Inclusion Criteria Phase I * Patients must have a histologically confirmed malignancy that is to receive exclusively ICIs (no chemotherapy or RT in combination) per standard of care during the time in which lactulose will be administered. This includes, but is not limited to, melanoma, cutaneous squamous cell carcinoma, non-small cell lung cancer, mesothelioma, head and neck squamous cell carcinoma, classical Hodgkin lymphoma, primary mediastinal large B-cell lymphoma, urothelial cancer, MSI/MMRd cancer, cancers with high tumor mutational burden (\>=10 muts/mB), esophage…

Interventions

Drug
Lactulose
Lactulose 10 g daily with standard-of-care Immune checkpoint inhibitors (ICIs).

Location

University of Chicago Medicine Comprehensive Cancer Center
Chicago, Illinois

Bifidobacterium Lactulose Optimization in Oncology and Microbiome (BLOOM)

Summary

Eligibility

Interventions

Location

Compensation

Run this study?

Details

Conditions